Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,098 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Exacerbation of CMV and Nontuberculous Mycobacterial Infections Following PD-1 Blockade for HIV-Associated Kaposi Sarcoma.
Anidi IU, Sakai S, Brooks K, Fling SP, Wagner MJ, Lurain K, Lindestam Arlehamn CS, Sette A, Knox KS, Brenchley JM, Uldrick TS, Sharon E, Barber DL. Anidi IU, et al. Among authors: sette a. Open Forum Infect Dis. 2024 Mar 31;11(5):ofae183. doi: 10.1093/ofid/ofae183. eCollection 2024 May. Open Forum Infect Dis. 2024. PMID: 38680611 Free PMC article. Clinical Trial.
The Impact of Diabetes and Prediabetes on Prevalence of Mycobacterium tuberculosis Infection Among Household Contacts of Active Tuberculosis Cases in Ethiopia.
Smith AGC, Kempker RR, Wassie L, Bobosha K, Nizam A, Gandhi NR, Auld SC, Magee MJ, Blumberg HM; Tuberculosis Research Unit: Role of Antigen Specific Responses in the Control of TB (TBRU-ASTRa) Study Group. Smith AGC, et al. Open Forum Infect Dis. 2022 Jun 30;9(7):ofac323. doi: 10.1093/ofid/ofac323. eCollection 2022 Jul. Open Forum Infect Dis. 2022. PMID: 36420425 Free PMC article.
Corrigendum: Comparison of the frequency and phenotypic profile of Mycobacterium tuberculosis-specific CD4 T cells between the site of disease and blood in pericardial tuberculosis.
Du Bruyn E, Ruzive S, Howlett P, Cerrone M, Jacobs AJ, Lindestam Arlehamn CS, Sette A, Sher A, Mayer-Barber KD, Barber DL, Mayosi B, Ntsekhe M, Wilkinson RJ, Riou C. Du Bruyn E, et al. Among authors: sette a. Front Immunol. 2023 Feb 6;14:1141704. doi: 10.3389/fimmu.2023.1141704. eCollection 2023. Front Immunol. 2023. PMID: 36825021 Free PMC article.
Antigen Discovery for Next-Generation Pertussis Vaccines Using Immunoproteomics and Transposon-Directed Insertion Sequencing.
Gregg KA, Wang Y, Warfel J, Schoenfeld E, Jankowska E, Cipollo JF, Mayho M, Boinett C, Prasad D, Brickman TJ, Armstrong SK, Parkhill J, Da Silva Antunes R, Sette A, Papin JF, Wolf R, Merkel TJ. Gregg KA, et al. Among authors: sette a. J Infect Dis. 2023 Feb 14;227(4):583-591. doi: 10.1093/infdis/jiac502. J Infect Dis. 2023. PMID: 36575950 Free PMC article.
Mpox vaccine and infection-driven human immune signatures: an immunological analysis of an observational study.
Cohn H, Bloom N, Cai GY, Clark JJ, Tarke A, Bermúdez-González MC, Altman DR, Lugo LA, Lobo FP, Marquez S; PVI study group; Chen JQ, Ren W, Qin L, Yates JL, Hunt DT, Lee WT, Crotty S, Krammer F, Grifoni A, Sette A, Simon V, Coelho CH. Cohn H, et al. Among authors: sette a. Lancet Infect Dis. 2023 Nov;23(11):1302-1312. doi: 10.1016/S1473-3099(23)00352-3. Epub 2023 Jul 17. Lancet Infect Dis. 2023. PMID: 37475115
Spike protein is a key target for stronger and more persistent T-cell responses-a study of mild and asymptomatic SARS-CoV-2 infection.
Ssali I, Mugaba S, Watelo AK, Bemanzi J, Katende JS, Oluka GK, Ankunda V, Baine C, Kato L; COVID-19 Immunoprofiling Team; Onyachi N, Muwanga M, Jjuuko M, Kayiwa J, Nsereko C, Auma BO, Weiskopf D, Sette A, Lutalo T, Musenero M, Kaleebu P, Serwanga J. Ssali I, et al. Among authors: sette a. Int J Infect Dis. 2023 Nov;136:49-56. doi: 10.1016/j.ijid.2023.09.001. Epub 2023 Sep 6. Int J Infect Dis. 2023. PMID: 37683720 Free article.
Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responses.
Ramirez SI, Grifoni A, Weiskopf D, Parikh UM, Heaps A, Faraji F, Sieg SF, Ritz J, Moser C, Eron JJ, Currier JS, Klekotka P, Sette A, Wohl DA, Daar ES, Hughes MD, Chew KW, Smith DM, Crotty S; Accelerating COVID-19 Therapeutic Interventions and Vaccines–2/A5401 (ACTIV-2/A5401) Study Team. Ramirez SI, et al. Among authors: sette a. JCI Insight. 2022 Dec 22;7(24):e163471. doi: 10.1172/jci.insight.163471. JCI Insight. 2022. PMID: 36378539 Free PMC article.
Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination.
Geers D, Sablerolles RSG, van Baarle D, Kootstra NA, Rietdijk WJR, Schmitz KS, Gommers L, Bogers S, Nieuwkoop NJ, van Dijk LLA, van Haren E, Lafeber M, Dalm VASH, Goorhuis A, Postma DF, Visser LG, Huckriede ALW, Sette A, Grifoni A, de Swart RL, Koopmans MPG, van der Kuy PHM, GeurtsvanKessel CH, de Vries RD; SWITCH research group. Geers D, et al. Among authors: sette a. iScience. 2023 Jan 20;26(1):105753. doi: 10.1016/j.isci.2022.105753. Epub 2022 Dec 7. iScience. 2023. PMID: 36507223 Free PMC article.
1,098 results